Early-stage regulatory strategy is becoming a powerful driver of speed, risk reduction, and commercial value in drug ...

The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development, and its work ...

The collaboration achieves synergy across the entire value chain from AI-driven design and antibody development to payload-linker chemical synthesis and clinical development, establishing a complete, ...

Forbes contributors publish independent expert analyses and insights. Sai writes about healthcare, innovation and technology. The last two years have witnessed explosive growth in the implementation ...

Learn how AI is transforming predictions of drug-induced liver injury and aiding drug development for safer therapeutics.

CDMOs are re-evaluating a reliance on China and increasingly turning to nearshoring and friendshoring for supply chain ...

Too often, manufacturing is treated as an afterthought in drug development—a downstream function to be addressed once R&D milestones are met. But in today’s complex and competitive environment, ...

Insilico Medicine ("Insilico"), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a multi-year research and development (R&D) collaboration with Servier, an ...